Loading
A phase 3 trial of Atezolizumab, Cisplatin, Vinorelbine in non-small-cell lung cancer and small-cell lung cancer, run by Hoffmann-La Roche, active and no longer recruiting.
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] is a phase 3 interventional study registered as NCT02486718 by Hoffmann-La Roche, with 1280 participants enrolled, started 2015-10-31 and due to reach its primary completion in 2024-01-26. Interventions recorded: Atezolizumab, Cisplatin, Vinorelbine, Docetaxel, Gemcitabine. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
1,280 enrolled.
Registry results, up to 95 months; 95% CI 51.8 to not reached · 95% CI 30.1 to 57.8
Source95% CI 42.2 to not reached · 95% CI 31.4 to 57.1
Source95% CI 52.4 to not reached · 95% CI 37.0 to 65.8
SourceMedian follow-up 32.2 months
Source53 patients; grade 5 events in 4 (1%)
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Disease-free survival, stage II to IIIA with PD-L1 on 1% or more of tumour cellsprimary | Atezolizumab after adjuvant chemotherapy | - | 68.5 months | 0.704 (0.545 to 0.91) | - | link |
| Best supportive care | - | 37.3 months | ||||
| Disease-free survival, all randomised stage II to IIIAprimary | Atezolizumab after adjuvant chemotherapy | - | 57.4 months | 0.83 (0.691 to 0.998) | - | link |
| Best supportive care | - | 40.8 months | ||||
| Disease-free survival, intention-to-treat population (stage IB to IIIA)primary | Atezolizumab after adjuvant chemotherapy | 507 | 65.6 months | 0.848 (0.71 to 1.013) | 0.0683 | link |
| Best supportive care | 498 | 47.8 months | ||||
| Disease-free survival at the primary analysis (Lancet 2021), stage II to IIIA with PD-L1 on 1% or more of tumour cells | Atezolizumab after adjuvant chemotherapy | - | Median follow-up 32.2 months | 0.66 (0.5 to 0.88) | 0.0039 | link |
| Best supportive care | - | - | ||||
| Atezolizumab-related grade 3 to 4 adverse events | Atezolizumab after adjuvant chemotherapy | 495 | 11% | - | - | link |
A second publication from the trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
Adjuvant immunotherapy entered lung cancer here, and with it the question that still divides practice: whether it is better given before the operation, after it, or on both sides.
Shares Vinorelbine, Atezolizumab, Resectable stage I to III non-small-cell lung cancer, Pemetrexed.
Shares Vinorelbine, ADAURA, Resectable stage I to III non-small-cell lung cancer, Platinum agents.
Shares Roche / Genentech, Pemetrexed, Platinum agents, Cisplatin.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Gemcitabine, Platinum agents.
Shares Vinorelbine, ADAURA, Resectable stage I to III non-small-cell lung cancer, Platinum agents.
Shares Atezolizumab, Roche / Genentech, Pemetrexed, Gemcitabine.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Gemcitabine, Cisplatin.
Shares Pemetrexed, Gemcitabine, Platinum agents, Cisplatin.